Previous Article | Next Article ![]()
Journal of Clinical Microbiology, June 2006, p. 2280-2282, Vol. 44, No. 6
0095-1137/06/$08.00+0 doi:10.1128/JCM.02187-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Clinical Virology Department, GlaxoSmithKline, Research Triangle Park, North Carolina
Received 18 October 2005/ Returned for modification 15 December 2005/ Accepted 15 March 2006
We evaluated the performance characteristics of a new, real-time nucleic acid sequence-based amplification (NASBA) assay that incorporates molecular beacon technology for detection of human immunodeficiency virus type 1 (HIV-1). The quantitative results were comparable to those obtained with three leading commercially available assays. The analytical sensitivity was 37 IU/ml. The NASBA assay detected clinically relevant recombinant viruses and all group M HIV-1 subtypes.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»